Abstract:
BACKGROUND. Prostate cancer which is the second most common cause of death among
men has a high incidence in recent years. Current therapeutic regimens should be improved
to overcome drug resistance. At the metastatic stage, tumors become refractory to established
chemotherapeutic treatments and cause serious problems at the clinics. Development of new
drug molecules that are able to transport through the membrane easily and kill tumor cells
rapidly is of great interest.
METHOD. In the current study, a novel Heterodinuclear copper(II)Mn(II) Schiff base
complex combined with P85 was used for prostate cancer treatment in vivo. Tramp-C1 cells
injected animals were subjected to chemotherapeutic formulation treatment and results were
analyzed by toxicology analysis, tumor volume measurements, and histopathological
analysis. 0.5 mg/kg Schiff base was selected and combined with 0.05% P85 according to the
toxicology analysis showing the enzyme levels, blood parameters, and multiple organ
toxicity.
RESULTS. Results demonstrated that Heterodinuclear copper(II)Mn(II) complex-P85 combination
decreased tumor formation and tumor volume steadily over the course of experiments.
CONCLUSIONS. Overall, Heterodinuclear copper(II)Mn(II) complex-P85 exerted remarkable
anti-cancer activity in vivo in C57/B16 mice. Prostate 76:1454–1463, 2016.
# 2016 Wiley Periodicals, Inc.
